Chau T. Dang

14.2k total citations · 3 hit papers
165 papers, 5.3k citations indexed

About

Chau T. Dang is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Chau T. Dang has authored 165 papers receiving a total of 5.3k indexed citations (citations by other indexed papers that have themselves been cited), including 137 papers in Oncology, 69 papers in Cancer Research and 39 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Chau T. Dang's work include HER2/EGFR in Cancer Research (104 papers), Cancer Treatment and Pharmacology (71 papers) and Breast Cancer Treatment Studies (62 papers). Chau T. Dang is often cited by papers focused on HER2/EGFR in Cancer Research (104 papers), Cancer Treatment and Pharmacology (71 papers) and Breast Cancer Treatment Studies (62 papers). Chau T. Dang collaborates with scholars based in United States, United Kingdom and Canada. Chau T. Dang's co-authors include Clifford A. Hudis, Monica Morrow, Tracy‐Ann Moo, Rachel Sanford, Larry Norton, Babette B. Weksler, Anthony F. Yu, Andrew J. Dannenberg, Richard M. Steingart and Kotha Subbaramaiah and has published in prestigious journals such as New England Journal of Medicine, Circulation and The Journal of Experimental Medicine.

In The Last Decade

Chau T. Dang

157 papers receiving 5.2k citations

Hit Papers

3 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer

2015 458 citations Sara M. Tolaney, Chau T. Dang et al. profile →
Overview of Breast Cancer Therapy

2018 341 citations Chau T. Dang et al. profile →
Efficacy of Exercise Therapy on Cardiorespiratory Fitness in Patients With Cancer: A Systematic Review and Meta-Analysis

2018 237 citations Jessica M. Scott, Tormod S. Nilsen et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Chau T. Dang United States	39	3.2k	1.4k	1.3k	979	839	165	5.3k
Amy S. Clark United States	30	2.3k 0.7×	965 0.7×	1.2k 1.0×	379 0.4×	2.4k 2.9×	108	5.4k
Bryan P. Schneider United States	37	3.3k 1.0×	1.1k 0.8×	1.2k 0.9×	209 0.2×	1.7k 2.0×	165	6.3k
Carmen Criscitiello Italy	44	4.4k 1.4×	2.2k 1.6×	1.5k 1.2×	986 1.0×	1.5k 1.8×	202	7.0k
Alessandra Gennari Italy	32	2.4k 0.7×	1.2k 0.9×	773 0.6×	687 0.7×	1.5k 1.8×	164	4.8k
Francesco Cognetti Italy	46	5.0k 1.6×	1.7k 1.2×	2.3k 1.8×	283 0.3×	2.4k 2.8×	221	8.5k
Andrew D. Seidman United States	50	8.1k 2.5×	2.2k 1.6×	2.5k 1.9×	1.2k 1.2×	2.2k 2.6×	211	11.1k
Epie Boven Netherlands	45	3.3k 1.0×	1.1k 0.8×	2.0k 1.6×	322 0.3×	3.0k 3.5×	190	7.5k
Mourad Tighiouart United States	38	1.7k 0.5×	700 0.5×	930 0.7×	341 0.3×	1.6k 1.9×	152	5.0k
Gerald A. Soff United States	41	962 0.3×	1.3k 0.9×	683 0.5×	1.1k 1.2×	2.1k 2.6×	137	5.7k
Rossana Berardi Italy	45	4.2k 1.3×	1.4k 1.0×	2.8k 2.2×	285 0.3×	1.9k 2.2×	344	7.4k

Countries citing papers authored by Chau T. Dang

Since Specialization

Citations

This map shows the geographic impact of Chau T. Dang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chau T. Dang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chau T. Dang more than expected).

Fields of papers citing papers by Chau T. Dang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chau T. Dang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chau T. Dang. The network helps show where Chau T. Dang may publish in the future.

Co-authorship network of co-authors of Chau T. Dang

This figure shows the co-authorship network connecting the top 25 collaborators of Chau T. Dang. A scholar is included among the top collaborators of Chau T. Dang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chau T. Dang. Chau T. Dang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ferraro, Emanuela, Anne S. Reiner, Umberto Tosi, et al.. (2025). Survival Among Patients With ERBB2-Positive Metastatic Breast Cancer and Central Nervous System Disease. JAMA Network Open. 8(1). e2457483–e2457483. 1 indexed citations

Ferraro, Emanuela, Atif J. Khan, George Plitas, et al.. (2024). Abstract PO3-04-07: Characterization of response to first-line chemotherapy, trastuzumab, and pertuzumab among patients with de novo metastatic HER2-positive breast cancer. Cancer Research. 84(9_Supplement). PO3–4. 1 indexed citations

Yu, Anthony F., Chau T. Dang, Chaya S. Moskowitz, et al.. (2023). Rationale and design of a cardiac safety study for reduced cardiotoxicity surveillance during HER2-targeted therapy. Cardio-Oncology. 9(1). 13–13. 4 indexed citations

Ferraro, Emanuela, Anton Safonov, Yuan Chen, et al.. (2023). Abstract P4-02-01: Efficacy of HER2 ADCs against HER2 inhibitor resistance alterations in the PI3K and MAPK pathways in HER2-positive breast cancer. Cancer Research. 83(5_Supplement). P4–2. 2 indexed citations

Shen, Fei, Guanglong Jiang, Santosh Philips, et al.. (2023). Cytochrome P450 Oxidoreductase ( POR ) Associated with Severe Paclitaxel-Induced Peripheral Neuropathy in Patients of European Ancestry from ECOG-ACRIN E5103. Clinical Cancer Research. 29(13). 2494–2500. 2 indexed citations

Swain, Sandra M., Antoinette R. Tan, Luca Gianni, et al.. (2022). Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancer. European Journal of Cancer. 178. 70–81. 4 indexed citations

Sella, Tal, Yue Zheng, Nabihah Tayob, et al.. (2022). Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT). npj Breast Cancer. 8(1). 127–127. 5 indexed citations

Khoury, Katia, Filipa Lynce, Ana Barac, et al.. (2021). Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function. Breast Cancer Research and Treatment. 185(3). 863–868. 20 indexed citations

Ren, Yan, et al.. (2020). SNHG6 Interacted with miR-325-3p to Regulate Cisplatin Resistance of Gastric Cancer by Targeting GITR. SHILAP Revista de lepidopterología. 1 indexed citations

10.

Wang, Rui, Lillian M. Smyth, Neil M. Iyengar, et al.. (2019). Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up. The Oncologist. 24(8). e646–e652. 6 indexed citations

11.

Scott, Jessica M., Neil M. Iyengar, Tormod S. Nilsen, et al.. (2018). Feasibility, safety, and efficacy of aerobic training in pretreated patients with metastatic breast cancer: A randomized controlled trial. Cancer. 124(12). 2552–2560. 85 indexed citations

12.

Jones, Lee W., Marilyn L. Kwan, Erin Weltzien, et al.. (2016). Exercise and Prognosis on the Basis of Clinicopathologic and Molecular Features in Early-Stage Breast Cancer: The LACE and Pathways Studies. Cancer Research. 76(18). 5415–5422. 42 indexed citations

13.

Yu, Anthony F., Carlos Manrique, Jennifer E. Liu, et al.. (2016). Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer. The Oncologist. 21(4). 418–424. 38 indexed citations

14.

Iyengar, Neil M., Monica Fornier, Steven Sugarman, et al.. (2015). A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer. Clinical Breast Cancer. 16(2). 87–94. 2 indexed citations

15.

Yu, Anthony F., Anne Eaton, Howard T. Thaler, et al.. (2014). Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer. Breast Cancer Research and Treatment. 149(2). 489–495. 68 indexed citations

16.

Dang, Chau T., Neil M. Iyengar, Gabriella D’Andrea, et al.. (2014). Phase II Study of Paclitaxel Given Once per Week Along With Trastuzumab and Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer. Journal of Clinical Oncology. 33(5). 442–447. 55 indexed citations

17.

Morris, Patrick G., Neil M. Iyengar, Sujata Patil, et al.. (2013). Long‐term cardiac safety and outcomes of dose‐dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer. Cancer. 119(22). 3943–3951. 15 indexed citations

18.

Morris, Patrick G., Xi Kathy Zhou, Ginger L. Milne, et al.. (2013). Increased Levels of Urinary PGE-M, a Biomarker of Inflammation, Occur in Association with Obesity, Aging, and Lung Metastases in Patients with Breast Cancer. Cancer Prevention Research. 6(5). 428–436. 57 indexed citations

19.

Drucker, Aaron M., Shenhong Wu, Chau T. Dang, & Mario E. Lacouture. (2012). Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis. Breast Cancer Research and Treatment. 135(2). 347–354. 26 indexed citations

20.

Dang, Chau T., Nancy U. Lin, Beverly Moy, et al.. (2010). Dose-Dense Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel With Trastuzumab and Lapatinib in HER2/neu–Overexpressed/Amplified Breast Cancer Is Not Feasible Because of Excessive Diarrhea. Journal of Clinical Oncology. 28(18). 2982–2988. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact